U.S. markets open in 5 hours 13 minutes

Zimmer Biomet Holdings, Inc. (ZBH)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
133.37-5.23 (-3.77%)
At close: 4:03PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inverted Hammer

Inverted Hammer

Previous Close138.60
Open135.88
Bid0.00 x 800
Ask133.74 x 1200
Day's Range132.74 - 136.00
52 Week Range74.37 - 161.11
Volume1,734,603
Avg. Volume975,864
Market Cap27.614B
Beta (5Y Monthly)1.35
PE Ratio (TTM)749.27
EPS (TTM)0.18
Earnings DateNov 06, 2020
Forward Dividend & Yield0.96 (0.69%)
Ex-Dividend DateSep 29, 2020
1y Target Est152.73
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-37% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Stryker (SYK) to Report Q3 Earnings: What's in the Cards?
    Zacks

    Stryker (SYK) to Report Q3 Earnings: What's in the Cards?

    Stryker's (SYK) third-quarter results are likely to reflect weak segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

  • Were Hedge Funds Right About Crowding Into Zimmer Biomet Holdings Inc (ZBH)?
    Insider Monkey

    Were Hedge Funds Right About Crowding Into Zimmer Biomet Holdings Inc (ZBH)?

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • Zimmer Biomet Empowers Joint Surgery Candidates Who Have Delayed Procedures: "Don't Let Pain Gain On You"
    PR Newswire

    Zimmer Biomet Empowers Joint Surgery Candidates Who Have Delayed Procedures: "Don't Let Pain Gain On You"

    Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today launched Don't Let Pain Gain on You, a multimedia campaign to inform and empower people who have delayed joint replacement surgery to have a conversation with their healthcare professional about confidently moving forward with their procedure. The campaign is informed by the results of a new U.S. survey that reveals nearly half (48%) of joint replacement surgery candidates have postponed treatment due to fears stemming from the COVID-19 pandemic.1